Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine

References

• United Nations Programme on HIV/AIDS Data Table 2011 Geneva United Nations Programme on HIV/AIDS 2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf Accessed July 3, 2013
   Google Scholar
• United Nations Programme on HIV/AIDS UNAIDS Report on the Global AIDS Epidemic: 2010 Geneva United Nations Programme on HIV/AIDS 2010 Available from: http://www.unaids.org/documents/20101123_GlobalReport_em.pdf Accessed May 23, 2013
   Google Scholar
• United Nations Programme on HIV/AIDS UNAIDS World AIDS Day Report 2011 Geneva United Nations Programme on HIV/AIDS 2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf Accessed June 20, 2013
   Google Scholar
• Abdool Karim Q Abdool Karim SS Frohlich JA CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 2010 329 5996 1168 1174 20643915
   PubMed Web of Science ®Google Scholar
• Gengiah TN Baxter C Mansoor LE Kharsany AB Abdool Karim SS A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection Expert Opin Investig Drugs 2012 21 5 695 715
   PubMed Web of Science ®Google Scholar
• van der Straten A Van Damme L Haberer JE Bangsberg DR Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention AIDS 2012 26 7 F13 F19 22333749
   PubMed Web of Science ®Google Scholar
• Kiser PF Mahalingam A Fabian J Design of tenofovir-UC781 combination microbicide vaginal gels J Pharm Sci 2012 101 5 1852 1864 22359356
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases Safety and effectiveness of tenofovir 1% gel, Tenofovir disproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate tablets in preventing HIV in women Available from: http://clinicaltrials.gov/ct2/show/NCT00705679. NLM identifier: NCT00705679 Accessed: May 29, 2013
   Google Scholar
• Montgomery ET van der Straten A Cheng H Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use AIDS Behav 2012 16 7 1787 1798 22790902
   PubMed Web of Science ®Google Scholar
• Mesquita PM Rastogi R Segarra TJ Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection J Antimicrob Chemother 2012 67 7 1730 1738 22467632
   PubMed Web of Science ®Google Scholar
• Moss JA Malone AM Smith TJ Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring Antimicrob Agents Chemother 2012 56 2 875 882 22123689
   PubMed Web of Science ®Google Scholar
• Moss JA Malone AM Smith TJ Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques Antimicrob Agents Chemother 2012 56 11 5952 5960 22964245
   PubMed Web of Science ®Google Scholar
• Malcolm RK Woolfson AD Toner CF Morrow RJ McCullagh SD Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings J Antimicrob Chemother 2005 56 5 954 956 16155060
   PubMed Web of Science ®Google Scholar
• Hussain A Ahsan F The vagina as a route for systemic drug delivery J Control Release 2005 103 2 301 313 15763615
   PubMed Web of Science ®Google Scholar
• Fox R Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development Lupus 1996 5 (1 suppl)(suppl 1) S4 S10 8803903
   PubMed Web of Science ®Google Scholar
• Chung HS Hann SK Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine J Dermatol 1997 24 9 569 572 9350102
   PubMedGoogle Scholar
• Ben-Zvi I Kivity S Langevitz P Shoenfeld Y Hydroxychloroquine: from malaria to autoimmunity Clin Rev Allergy Immunol 2012 42 2 145 153 21221847
   PubMed Web of Science ®Google Scholar
• Hackstadt T Williams JC Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii Proc Natl Acad Sci U S A 1981 78 5 3240 3244 6942430
   PubMed Web of Science ®Google Scholar
• Raoult D Houpikian P Tissot Dupont H Riss JM Arditi-Djiane J Brouqui P Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine Arch Intern Med 1999 159 2 167 173 9927100
   PubMedGoogle Scholar
• Fenollar F Fournier PE Carrieri MP Habib G Messana T Raoult D Risks factors and prevention of Q fever endocarditis Clin Infect Dis 2001 33 3 312 316 11438895
   PubMed Web of Science ®Google Scholar
• Chiang G Sassaroli M Louie M Chen H Stecher VJ Sperber K Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine Clin Ther 1996 18 6 1080 1092 9001825
   PubMed Web of Science ®Google Scholar
• Sperber K Kalb TH Stecher VJ Banerjee R Mayer L Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T-cells and monocytes AIDS Res Hum Retroviruses 1993 9 1 91 98 8427717
   PubMed Web of Science ®Google Scholar
• Naarding MA Baan E Pollakis G Paxton WA Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes Retrovirology 2007 4 1 6 17263871
   PubMed Web of Science ®Google Scholar
• Rayne F Vendeville A Bonhoure A Beaumelle B The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity J Virol 2004 78 21 12054 12057 15479845
   PubMed Web of Science ®Google Scholar
• Sperber K Louie M Kraus T Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1 Clin Ther 1995 17 4 622 636 8565026
   PubMed Web of Science ®Google Scholar
• Paton NI Aboulhab J Karim F Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1 Lancet 2002 359 9318 1667 1668 12020529
   PubMed Web of Science ®Google Scholar
• Gilman AL Chan KW Mogul A Hydroxychloroquine for the treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 2006 3A 327 334
   Google Scholar
• Goldman FD Gilman AL Hollenback C Kato RM Premack BA Rawlings DJ Hydroxychloroquine inhibits calcium signals in T-cells: a new mechanism to explain its immunomodulatory properties Blood 2000 95 11 3460 3466 10828029
   PubMed Web of Science ®Google Scholar
• Piconi S Parisotto S Rizzardini G Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders Blood 2011 118 12 3263 3272 21576701
   PubMed Web of Science ®Google Scholar
• Shattock RJ Moore JP Inhibiting sexual transmission of HIV-1 infection Nat Rev Microbiol 2003 1 1 25 34 15040177
   PubMed Web of Science ®Google Scholar
• Promadej-Lanier N Smith JM Srinivasan P Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates J Med Primatol 2009 38 4 263 271 19476564
   PubMed Web of Science ®Google Scholar
• Johnson TJ Gupta KM Fabian J Albright TH Kiser PF Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir Eur J Pharm Sci 2010 39 4 203 212 19958831
   PubMed Web of Science ®Google Scholar
• Volin P Simple and specific reversed-phase liquid chromatographic method with diode-array detection for simultaneous determination of serum hydroxychloroquine, chloroquine and some corticosteroids J Chromatogr B Biomed Appl 1995 666 2 347 353 7633613
   PubMed Web of Science ®Google Scholar
• Kiser PF Johnson TJ Clark JT State of the art in intravaginal ring technology for topical prophylaxis of HIV infection AIDS Rev 2012 14 1 62 77 22297505
   PubMed Web of Science ®Google Scholar
• Vermesh M Fossum GT Kletzky OA Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women Obstet Gynecol 1988 72 5 693 698 3173919
   PubMed Web of Science ®Google Scholar
• Patel LG Warrington SJ Pearson RM Propranolol concentrations in plasma after insertion into the vagina Br Med J (Clin Res Ed) 1983 287 6401 1247 1248
   Web of Science ®Google Scholar
• D’Cruz OJ Uckun FM Vaginal microbicides and their delivery platforms Expert Opin Drug Deliv 2014 11 5 723 740 24506783
   PubMed Web of Science ®Google Scholar
• Woolfson ADRM Rathbone MJ Hadgraft J Intravaginal Drug Delivery Technologies New York Marcel Dekker 2008 754 774
   Google Scholar
• Srikrishna S Cardozo L The vagina as a route for drug delivery: a review Int Urogynecol J 2013 24 4 537 543 23229421
   PubMed Web of Science ®Google Scholar
• Ho EA Intravaginal Rings as a Novel Platform for Mucosal Vaccination J Mol Pharm Org Process Res 2013 1 2 e103
   Google Scholar
• Lajoie J Juno J Burgener A A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers Mucosal Immunol 2012 5 3 277 287 22318497
   PubMed Web of Science ®Google Scholar
• Iqbal SM Ball TB Kimani J Elevated T-cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers J Infect Dis 2005 192 5 728 738 16088822
   PubMed Web of Science ®Google Scholar
• Songok EM Luo M Liang B Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state PLoS ONE 2012 7 1 e30048 22291902
   PubMed Web of Science ®Google Scholar
• Tsai WP Nara PL Kung HF Oroszlan S Inhibition of human immunodeficiency virus infectivity by chloroquine AIDS Res Hum Retroviruses 1990 6 4 481 489 1692728
   PubMed Web of Science ®Google Scholar
• Saltzman W Drug Delivery: Engineering Principles for Drug Therapy New York Oxford University Press 2001
   Google Scholar
• Clark JT Clark MR Shelke NB Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy PLoS ONE 2014 9 3 e88509 24599325
   PubMed Web of Science ®Google Scholar
• Clark MR Johnson TJ McCabe RT A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781 J Pharm Sci 2012 101 2 576 587 21976110
   PubMed Web of Science ®Google Scholar
• Malcolm RK Edwards KL Kiser P Romano J Smith TJ Advances in microbicide vaginal rings Antiviral Res 2010 88 suppl 1 S30 S39 21109066
   PubMed Web of Science ®Google Scholar
• Johnson TJ Clark MR Albright TH A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis Antimicrob Agents Chemother 2012 56 12 6272 6283 23006751
   PubMed Web of Science ®Google Scholar
• Clark JT Johnson TJ Clark MR Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir J Control Release 2012 163 2 240 248 22981701
   PubMed Web of Science ®Google Scholar
• Malcolm RK Fetherston SM McCoy CF Boyd P Major I Vaginal rings for delivery of HIV microbicides Int J Womens Health 2014 595 605
   Google Scholar
• Fan C Pai-Thakur R Phuapradit W Impact of polymers on dissolution performance of an amorphous gelleable drug from surface-coated beads Eur J Pharm Sci 2009 37 1 1 10 19027852
   PubMed Web of Science ®Google Scholar
• Ensslin S Moll KP Paulus K Mäder K New insight into modified release pellets – Internal structure and drug release mechanism J Control Release 2008 128 2 149 156 18433911
   PubMed Web of Science ®Google Scholar
• Shen J Burgess DJ Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings Int J Pharm 2012 422 1–2 341 348 22016033
   PubMed Web of Science ®Google Scholar
• Siepmann F Eckart K Maschke A Kolter K Siepmann J Modeling drug release from PVAc/PVP matrix tablets J Control Release 2010 141 2 216 222 19737588
   PubMed Web of Science ®Google Scholar
• Johnson TJ Clark MR Albright TH A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis Antimicrob Agents Chemother 2012 56 12 6272 6283 23006751
   PubMed Web of Science ®Google Scholar
• Balraj Saini GB Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn and LC-MS-TOF studies J Pharm Biomed Anal 2013
   Web of Science ®Google Scholar
• Ferriter JP Meyers CEJr Lorton L The effect of hydrogen ion concentration on the force-degradation rate of orthodontic polyurethane chain elastics Am J Orthod Dentofacial Orthop 1990 98 5 404 410 2239838
   PubMed Web of Science ®Google Scholar
• Mesquita PM Cheshenko N Wilson SS Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety J Infect Dis 2009 200 4 599 608 19586414
   PubMed Web of Science ®Google Scholar
• Fichorova RN Bajpai M Chandra N Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives Biol Reprod 2004 71 3 761 769 15128598
   PubMed Web of Science ®Google Scholar
• Franken NA Rodermond HM Stap J Haveman J van Bree C Clonogenic assay of cells in vitro Nat Protoc 2006 1 5 2315 2319 17406473
   PubMed Web of Science ®Google Scholar
• Li W Lam MS Birkeland A Cell-based assays for profiling activity and safety properties of cancer drugs J Pharmacol Toxicol Methods 2006 54 3 313 319 16675273
   PubMedGoogle Scholar
• Gustafsson RJ Ahrné S Jeppsson B The Lactobacillus flora in vagina and rectum of fertile and postmenopausal healthy Swedish women BMC Womens Health 2011 11 1 17 21609500
   PubMed Web of Science ®Google Scholar
• Angelakis E Million M Kankoe S Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment Antimicrob Agents Chemother 2014 58 6 3342 3347 24687497
   PubMed Web of Science ®Google Scholar
• Walter J Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research Appl Environ Microbiol 2008 74 16 4985 4996 18539818
   PubMed Web of Science ®Google Scholar